Imunon, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On June 4, 2026, Imunon raised $10 million in gross proceeds: $2.5 million from 250 shares of non-redeemable, non-convertible preferred stock and $7.72 million from two secured promissory notes (principal amounts $2.72M at 8% and $5.0M at 5%, maturing 18 months from issuance). Phase 3 OVATION 3 trial for lead candidate IMNN-001 in ovarian cancer is enrolling faster than forecast; Phase 2 OVATION 2 showed 14.7-month median OS benefit (45.1 vs. 30.4 months vs. standard of care). H1 2026 net loss was $7.1M on $7.1M operating expenses; cash position as of June 30, 2026 was $6.9M.
Why this rating
Capital raise of $10M is 47% of company's $21.2M market value—meaningful liquidity injection for clinical-stage biotech with strong Phase 2 data and accelerating Phase 3 enrollment. Material near-term positive for runway and trial advancement.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.